AUSTIN, Texas, October 15, 2015 — Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that it will present at the 2015 Achieving Optimal Health Conference (AOHC) in Washington, DC on October 24th. Valerie Palmieri, President and Chief Executive Officer of Vermillion, will speak on the “non-silent” symptoms associated with benign and malignant pelvic masses and how women may achieve better medical care through the use of modern diagnostic techniques, such as Vermillion’s OVA1® test.
“We’re delighted to join with AOHC to increase awareness on proactively managing pelvic health to a wider audience.” said Ms. Palmieri. “As we have previously stated, our primary goal is to lead with education, increase awareness and allow women to control their destiny and understand their pelvic mass disease, a disease which impacts 20 million patients on an-going basis in the US alone. Our outreach program has already begun, through our relationships with ovarian cancer and hereditary cancer advocacy groups, as well as our personalized ovarian cancer quiz located on our website at www.vermillion.com and our ASPiRA LABS Facebook page and Twitter account.”
About the Achieving Optimal Health Conference (AOHC)
Founded by Doro Bush Koch, Patricia Reilly Koch, Therese Burch and Patrice King Brickman, the 2015 AOHC is a conference dedicated to helping people reach optimal health by connecting them with the resources needed to learn how to nourish their bodies and minds. Attendees learn the importance of taking responsibility for their preventive healthcare measures. Presenters at the conference include leaders from Aetna, Inc., the Cleveland Clinic and Georgetown University. For more information, go to http://achievingoptimalhealthconference.com/.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic disease. The company’s lead diagnostic, OVA1, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.
About ASPiRA LABS
ASPiRA Labs is a diagnostic services laboratory founded by Vermillion, Inc., a leader in women’s health diagnostics. The laboratory’s goal is to provide high quality, innovative testing and bio-analytics for women to help address unmet women’s health needs. ASPiRA Labs’ specialized services are grounded in evidence-based medicine, while providing access to novel biomarker diagnostic tools designed to help health care professionals offer the most precise diagnoses and treatment guidance for their patients.
Investor Relations Contact:
LifeSci Advisors LLC